Rapport Therapeutics, Inc. (RAPP)

Every figure this model derived for RAPP, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 467,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 436,077,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 446,856,000 AssetsCurrent 2026-06-30
current liabilities 28,424,000 LiabilitiesCurrent 2026-06-30
equity 422,926,000 StockholdersEquity 2026-06-30
ocf -96,682,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 20,000,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 24,591,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up RAPP on one particular measure came for.

RatioValue
cash operating margin-639.83
current ratio15.72
current ratio reported15.72
dilution pct87.82
fcf margin-485.75
operating margin-767.58
owner earnings margin-608.7
sbc pct revenue122.95

What to be careful about

What this model itself distrusts about RAPP's figures. Written by the derivation as it ran, not added afterwards.